Teva acquires ecopipam, a Tourette's drug targeting D1 dopamine receptors, for $700M upfront plus $200M in contingent milestones.

Regeneron's FDA-approved gene therapy Otarmeni targets just 20–50 U.S. births yearly. Its free pricing strategy could cost every rare...

Agios reported a sharp step-up in Q1 2026 performance on the back of its U.S. launch of Aqvesme (mitapivat)...

Roche will unveil more than 45 ophthalmology abstracts at ARVO 2026, headlined by real-world data showing that Vabysmo improves...

Mesoblast reported a pivotal quarter: commercial sales of Ryoncil approached $100 million in the first year since launch, quarterly...

Organogenesis has completed a rolling Biologics License Application to the FDA for ReNu, a cryopreserved amniotic suspension allograft intended...

Zealand Pharma and Roche will advance petrelintide, a once-weekly amylin analog for chronic weight management, into Phase 3 trials...

Teva Pharmaceuticals has signed a definitive agreement to acquire Emalex Biosciences for $700 million upfront, with up to $200...

Teva's $900M Emalex deal for NDA-ready ecopipam in Tourette syndrome signals a pharma M&A shift: buy at Phase 3...

The U.S. Department of Justice and Drug Enforcement Administration have moved to reschedule certain cannabinoid-based products from Schedule I...